Olanzapine for the treatment of chronic refractory schizophrenia: A 12-month follow-up naturalistic study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 6, 2002, Pages 1055-1062

  Rodríguez Pérez, Víctor ^a   López, áurea ^a   Blanco, Clara ^a   Pea, Carmen ^a   López, Ana ^a   Abel, Ana ^a   Gómez, Yolanda ^a   Ferreiro, María José ^a   Rego, Carmen ^a   Cudeiro, Fernando ^a   álvarez, Vicente ^a   Prieto, Ramón ^a   Ciudad, Antonio ^a  

^a C/ Castro Riberas de Lea   (Spain)

Author keywords

Long term follow up; Olanzapine; Refractory schizophrenia

Indexed keywords

OLANZAPINE;

ADULT; AGED; AKATHISIA; ANALYSIS OF VARIANCE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LONGITUDINAL STUDY; MALE; PSYCHOLOGIC ASSESSMENT; RATING SCALE; SCHIZOPHRENIA; SYMPTOM; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BODY WEIGHT; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 0036775977     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00222-1     Document Type: Article

References (37)

1. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 154:1989;672-676.
2. Bhana N., Foster R.H., Olney R., Plosker G.L. Olanzapine: an updated of its use in the management of schizophrenia. Drugs. 61:2001;111-161.
3. Bondolfi G., Baumann P., Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur. Neuropsychopharmacol. 6(Suppl. 2):1996;S21-S25.
4. Breier A., Hamilton S.H. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry. 45:1999;403-411.
5. Christopher Q., Mountjoy M.B., Baldacchino A.M., Stubbs J.H. British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry. 156:1999;158-159.
6. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr. Bull. 23:1997;663-674.
7. Conley R.R., Tamminga C.A., Bartko J.J., Richardson C. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry. 155:1998;914-920.
8. Conley R.R., Tamminga C.A., Kelly D.L., Richardson C.M. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol. Psychiatry. 46:1999;73-77.
9. CPMP/EWP/559/95, 1998. Committee for Proprietary Medicinal Products. Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia. The European Agency for the Evaluation of Medicinal Products, London.
10. Duggan L., Fenton M., Dardennes R.M., El-Dosoy A., Indran S. Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2000;. CD001359.
11. Dursun S.M., Gardner D.M., Bird D.C., Flinn J. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can. J. Psychiatry. 44:1999;701-704.
12. Gómez J.C., Sacristán J.A., Hernández J., Breier A., Ruiz-Carrasco P., Antón-Saiz C., Fontova-Carbonell E. Pharmacoepidemiologic Study of Olanzapine in Schizophrenia The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study). J. Clin. Psychiatry. 61:2000;335-343.
13. Hellewell J.S. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J. Clin. Psychiatry. 60(Suppl. 23):1999;S14-S19.
14. Jones B., Basson B.R., Walker D.J., Crawford A.K., Kinon B.J. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J. Clin. Psychiatry. 62:2001;41-44.
15. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
16. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
17. Kinon B.J., Basson B.R., Gilmore J.A., Tollefson G.D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry. 62:2001;92-100.
18. Lieberman J.A., Kane J.M., Safferman A.Z. Predictors of response to clozapine. J. Clin. Psychiatry. 55(Suppl. B):1994;S126-S128.
19. Marsden C.D., Schachter M. Assessment of extrapyramidal disorders. Br. J. Clin. Pharmacol. 11:1981;129-151.
20. Martin J., Gómez J.C., García-Bernardo E., Cuesta M., Alvarez E., Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J. Clin. Psychiatry. 58:1997;479-483.
21. Meltzer H.Y. Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 14:1997;1-20.
22. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients: I. Preliminary report. Psychopharmacology. 99:1989;S68-S72. Supplement.
23. Moore N.A., Calligaro D.O., Wong D.T. The pharmacology of olanzapine and other antipsychotic agents. Curr. Opin. Invest. Drugs. 2:1993;281-293.
24. Overall J., Gorham D. Brief Psychiatric Rating Scale. Psychol. Rep. 10:1962;799.
25. Peuskens J. The evolving definition of treatment resistance. J. Clin. Psychiatry. 60(Suppl. 12):1999;S4-S8.
26. Pichot P., López-Ibor J.J., Valdés M. DSM-IV, Breviario. Criterios diagnósticos. Spanish version of the diagnostic criteria for the DSM-IV. 1995;147-160 Masson Ed. Barcelona.
27. Pichot P., López-Ibor J.J., Valdés M. DSM-IV, Breviario. Criterios diagnósticos. Spanish version of the diagnostic criteria for the DSM-IV. 1995;37-44 Masson Ed. Barcelona.
28. Pichot P., López-Ibor J.J., Valdés M. DSM-IV, Breviario. Criterios diagnósticos. Spanish version of the diagnostic criteria for the DSM-IV. 1995;45-46 Masson Ed. Barcelona.
29. Pisa M. Motor functions of the striatum of the rat; critical role of the lateral region in tongue and forelimb reaching. Neuroscience. 24:1988;453-463.
30. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional c-Fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
31. Reich J. Use of high-dose olanzapine in refractory psychosis. Am. J. Psychiatry. 156:1999;661.
32. Safferman A.Z., Lieberman J.A., Kane J.M., Szymanski S.R., Kinon B.J. Clozapina en la esquizofrenia refractaria al tratamiento. Shriqui C.L., Nasrallah H.A. Aspectos actuales en el tratamiento de la esquizofrenia. 1995;American Psychiatric Association Press, Washington, DC.
33. Sheitman B.B., Lieberman J.A. The natural history and pathophysiology of treatment resistant schizophrenia. J. Psychiatr. Res. 32:1988;143-150.
34. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212(Suppl. 45):1970;11-19.
35. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur. J. Pharmacol. 281:1995;289-294.
36. Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopaminergic neurons. Neuropsychopharmacology. 14:1996;97-104.
37. Vanelle J.M. Tratamiento de la esquizofrenia refractaria. Encépale. 21(Spec. No. 3):1995;13-21.